Standardization of regimens in Narrowband UVB and PUVA in early stage mycosis fungoides: position paper from the Italian Task Force for Cutaneous Lymphomas

2018 ◽  
Vol 32 (5) ◽  
pp. 683-691 ◽  
Author(s):  
V. Grandi ◽  
P. Fava ◽  
S. Rupoli ◽  
S. Alberti Violetti ◽  
L. Canafoglia ◽  
...  
Keyword(s):  
Mycosis Fungoides ◽  
Task Force ◽  
Early Stage ◽  
Position Paper ◽  
Narrowband Uvb ◽  
Cutaneous Lymphomas

Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)

Blood ◽  
2007 ◽  
Vol 110 (6) ◽  
pp. 1713-1722 ◽  
Author(s):  
Elise Olsen ◽  
Eric Vonderheid ◽  
Nicola Pimpinelli ◽  
Rein Willemze ◽  
Youn Kim ◽  
...  
Keyword(s):  
Mycosis Fungoides ◽  
Cell Biology ◽  
Task Force ◽  
Prognostic Significance ◽  
Staging System ◽  
Cutaneous Lymphoma ◽  
Sézary Syndrome ◽  
Sezary Syndrome ◽  
European Organization ◽  
Cutaneous Lymphomas

Abstract The ISCL/EORTC recommends revisions to the Mycosis Fungoides Cooperative Group classification and staging system for cutaneous T-cell lymphoma (CTCL). These revisions are made to incorporate advances related to tumor cell biology and diagnostic techniques as pertains to mycosis fungoides (MF) and Sézary syndrome (SS) since the 1979 publication of the original guidelines, to clarify certain variables that currently impede effective interinstitution and interinvestigator communication and/or the development of standardized clinical trials in MF and SS, and to provide a platform for tracking other variables of potential prognostic significance. Moreover, given the difference in prognosis and clinical characteristics of the non-MF/non-SS subtypes of cutaneous lymphoma, this revision pertains specifically to MF and SS. The evidence supporting the revisions is discussed as well as recommendations for evaluation and staging procedures based on these revisions.

scholarly journals Maintenance phototherapy for the treatment of early stage mycosis fungoides

2019 ◽  
Author(s):  
Soumaya Gara ◽  
Noureddine Litaiem ◽  
Takwa Bacha ◽  
Djamila Sandra OUEDRAOGO ◽  
Yosra Jmour ◽  
...  
Keyword(s):  
Mycosis Fungoides ◽  
Recurrence Rate ◽  
Early Stage ◽  
Maintenance Phase ◽  
Recurrence Free Survival ◽  
Free Survival ◽  
Early Stages ◽  
Stage Disease ◽  
Narrowband Uvb

Abstract Background : Phototherapy has been a mainstay of treatment of early stages (Ia-IIa) of mycosis fungoides (MF). Despite this, there is no internationally standardized phototherapy regimen schedule for MF. Efficacy of maintenance therapy is poorly evaluated especially in patients with dark phototype (IV-VI). Methods : Thirty patients with early stage MF treated with PUVA therapy and narrowband UVB therapy from January 2004 to January 2016 at a single institution were retrospectively reviewed. Recurrence rate and recurrence-free survival were assessed in patients who received maintenance phase and in those who underwent follow-up. Results : Seventeen patients had patch stage disease while 16 patients had plaque stage disease. Most of the patients (22, 73%) had dark phototype. Nineteen patients received NB-UVB therapy, while 11 patients received PUVA. Mean follow-up period was 36,1 + 13 months. There was no significant association between the recurrence rate and recurrence free survival in patients who received maintenance phase and those who underwent follow-up. Conclusions: Phototherapy is a safe and effective treatment option for patients with early stage MF. Evidence supporting the use of maintenance phase for the treatment of early stages MF is lacking.

scholarly journals TO THE QUESTION OF DIFFERENTIAL DIAGNOSIS OF T CELL SKIN LYMPHOMAS

2019 ◽  
Vol 22 (3-4) ◽  
pp. 68-72
Author(s):  
Olga Yu. Olisova ◽  
D. R Amshinskaya ◽  
E. M Anpilogova
Keyword(s):  
Differential Diagnosis ◽  
T Cell ◽  
Mycosis Fungoides ◽  
Current Literature ◽  
Lymphoid Tissue ◽  
Malignant Tumors ◽  
Early Stage ◽  
T Cell Lymphomas ◽  
Cutaneous Lymphomas ◽  
The World

Cutaneous T cell lymphomas (CTCL) are a clinically and morphologically heterogeneous group of cutaneous malignant tumors, caused by monoclonal proliferation of lymphoid tissue cells in the skin. They are responsible for about 80% of all primary cutaneous lymphomas, while cutaneous lymphomas are responsible for 2% of all dermatological diseases. The incidence of CTCL is now increasing all over the world. For this reason, CTCL has to be diagnosed on the early stage to improve course of the disease. Mycosis fungoides, the most frequent CTCL variant, is usually diagnosed basing on clinical, histological, immunohistochemical and molecular findings. However, it can imitate other chronic dermatoses, which makes it difficult to diagnose. The article presents a review of the current literature data on new diagnostic markers of cutaneous T-cell lymphomas.

Narrowband UVB phototherapy for early-stage mycosis fungoides

2002 ◽  
Vol 47 (2) ◽  
pp. 191-197 ◽  
Author(s):  
Raechele Cochran Gathers ◽  
Lubomira Scherschun ◽  
Farah Malick ◽  
David P. Fivenson ◽  
Henry W. Lim
Keyword(s):  
Mycosis Fungoides ◽  
Early Stage ◽  
Narrowband Uvb ◽  
Uvb Phototherapy

Narrowband UVB and psoralen-UVA in the treatment of early-stage mycosis fungoides: A retrospective study

2003 ◽  
Vol 48 (2) ◽  
pp. 215-219 ◽  
Author(s):  
Pascale V.M.M. Diederen ◽  
Huib van Weelden ◽  
Cornelus J.G. Sanders ◽  
Johan Toonstra ◽  
Willem A. van Vloten
Keyword(s):  
Retrospective Study ◽  
Mycosis Fungoides ◽  
Early Stage ◽  
Narrowband Uvb

scholarly journals Erythrodermic CD4/CD8 Double-Negative Mycosis Fungoides: A Case Report

2021 ◽  
pp. 256-261
Author(s):  
Monira Abdullah Alnasser ◽  
Nour Marwan AlKhawajah ◽  
Nada Ghazi AlQadri ◽  
Asem Mustafa Shadid ◽  
Fahad M. Alsaif
Keyword(s):  
T Cell ◽  
Mycosis Fungoides ◽  
Cell Lymphoma ◽  
Early Stage ◽  
Common Type ◽  
Lymphoproliferative Disorders ◽  
Cell Phenotype ◽  
Double Negative ◽  
Cutaneous T Cell Lymphoma ◽  
Cutaneous Lymphomas

Cutaneous T-cell lymphoma (CTCL) describes a group of lymphoproliferative disorders characterized by localization of neoplastic T lymphocytes to the skin. Mycosis fungoides (MF) represents the most common type of CTCL and accounts for ∼60% of all primary cutaneous lymphomas. Apart from the classic type of MF, many clinical and histopathologic variants have been described. The malignant lymphocytes in MF are usually CD3, CD4 and CD45RO positive and CD8 negative. An unusual immunohistochemical profile of a CD4-negative and CD8-positive mature T-cell phenotype has been reported in a minority of patients; up to 20% of early-stage MF demonstrates a CD8-positive phenotype. There are only a few cases of a double-negative CD4/CD8 MF phenotype reported in the literature. We present the case of a 60-year-old male presenting a double-negative CD4/CD8 MF phenotype.

TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC)

Blood ◽  
2007 ◽  
Vol 110 (2) ◽  
pp. 479-484 ◽  
Author(s):  
Youn H. Kim ◽  
Rein Willemze ◽  
Nicola Pimpinelli ◽  
Sean Whittaker ◽  
Elise A. Olsen ◽  
...  
Keyword(s):  
Mycosis Fungoides ◽  
International Society ◽  
Classification System ◽  
Task Force ◽  
Tnm Classification ◽  
Cutaneous Lymphoma ◽  
Sézary Syndrome ◽  
European Organization ◽  
Tnm System ◽  
Cutaneous Lymphomas

Abstract Currently availabel staging systems for non-Hodgkin lymphomas are not useful for clinical staging classification of most primary cutaneous lymphomas. The tumor, node, metastases (TNM) system used for mycosis fungoides (MF) and Sézary syndrome (SS) is not appropriate for other primary cutaneous lymphomas. A usable, unified staging system would improve the communication about the state of disease, selection of appropriate management, standardization of enrollment/response criteria in clinical trials, and collection/analysis of prospective survival data. Toward this goal, during the recent meetings of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC), the representatives have established a consensus proposal of a TNM classification system applicable for all primary cutaneous lymphomas other than MF and SS. Due to the clinical and pathologic heterogeneity of the cutaneous lymphomas, the currently proposed TNM system is meant to be primarily an anatomic documentation of disease extent and not to be used as a prognostic guide.

Sign in / Sign up

Export Citation Format

Share Document